Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03141177 · ClinicalTrials.gov registry record · Phase 3
A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
A Phase 3 study of Renal Cell Carcinoma, sponsored by Bristol-Myers Squibb.
- Active
- Registry status
- Phase 3
- Development phase
- 701
- Enrollment target
- 20
- Study locations
NCT03141177: Active Phase 3 study of Renal Cell Carcinoma, sponsored by Bristol-Myers Squibb.
NCT03141177 is a Phase 3 study of Renal Cell Carcinoma that is active but no longer recruiting, run by Bristol-Myers Squibb. The registered enrollment target is 701 participants, above the 237-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (196% higher). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03141177, a Phase 3 study of Renal Cell Carcinoma, is active but no longer recruiting, sponsored by Bristol-Myers Squibb.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 701 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine whether Nivolumab Combined with Cabozantinib is safe and effective compared to Sunitinib in previously untreated advanced or metastatic renal cell carcinoma
Primary Outcome
PFS is defined as the time from date of randomization to the first documented tumor progression date or death due to any cause, whichever occurs first based on BICR assessment using RECIST v1.1. Participants who die without a reported progression will be considered to have progressed on the date of their death. Participants who did not progress or die will be censored on the date of their last evaluable tumor assessment on or prior to initiation of subsequent anti-cancer therapy. Progressive dis
Conditions Studied
Interventions
- DRUG Sunitinib
- BIOLOGICAL Nivolumab
- DRUG Cabozantinib
- BIOLOGICAL Ipilimumab
Study Locations (20)
California
- Local Institution - 0133 - Bakersfield
- Local Institution - 0093 - Los Angeles
- Local Institution - 0090 - Redondo Beach
- Local Institution - 0088 - San Luis Obispo
- Central Coast Medical Oncology Corporation - Santa Maria
Arizona
- Local Institution - 0044 - Goodyear
- Local Institution - 0132 - Tucson
Georgia
- Local Institution - 0127 - Athens
- Local Institution - 0086 - Newnan
Illinois
- Local Institution - 0036 - Chicago
- Local Institution - 0042 - Zion
Massachusetts
- Local Institution - 0113 - Boston
- Local Institution - 0037 - Boston
Missouri
- Local Institution - 0106 - Kansas City
- Local Institution - 0035 - St Louis
Alabama
- Local Institution - 0077 - Daphne
Colorado
- Local Institution - 0103 - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 701 participants |
| Start Date | 2017-07-23 |
| Est. Completion | 2026-01-16 |
| Phase | Phase 3 |
What the registry record for NCT03141177 still lists
NCT03141177 is an interventional study that assigns participants to a tested intervention. The registered 701 participants enrollment target is mid-sized for trials with a published cap, above the 237-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (196% higher).
The record links to 1 condition, with Renal Cell Carcinoma appearing as the primary indexed condition, and to 4 interventions - of which Sunitinib is the first listed.
NCT03141177 names 20 study sites across 11 states, led by California, Arizona, Georgia.
Frequently Asked Questions
What is clinical trial NCT03141177 about?
NCT03141177 is a clinical study titled "A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma". The purpose of this study is to determine whether Nivolumab Combined with Cabozantinib is safe and effective compared to Sunitinib in previously untreated advanced or metastatic renal cell carcinoma
What is the current status of trial NCT03141177?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 701 participants. The study started on 2017-07-23. Estimated completion is 2026-01-16.
What conditions does trial NCT03141177 study?
This clinical trial studies the following conditions: Renal Cell Carcinoma.
What interventions are being tested in trial NCT03141177?
The interventions under investigation include: Sunitinib (DRUG), Nivolumab (BIOLOGICAL), Cabozantinib (DRUG), Ipilimumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT03141177?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03141177 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Renal Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03141177's enrollment target sits among peer trials
701 9th of 121 higher than 113 of 121 other Renal Cell Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Renal Cell Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)
RECRUITING · Phase 3
-
Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma
ACTIVE NOT RECRUITING · Phase 3
-
Dynamic Contrast Enhancement Computed Tomography for Evaluating Tumor Perfusion in Patients With Metastatic Renal Cell Carcinoma Receiving Targeted Therapies: Renal Cell Carcinoma (RCC) Scramble
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer
ACTIVE NOT RECRUITING · Phase 3
-
Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
ACTIVE NOT RECRUITING · Phase 3
-
Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06027996 · 702 participants · NA
Melodi Matrix™ in Breast Reconstruction
- NCT00900419 · 700 participants
Biomarkers in Patients With Respiratory Tract Dysplasia or Lung Cancer, Head and Neck Cancer, or Aerodigestive Tract Cancer and in Normal Volunteers
- NCT01804686 · 700 participants · Phase 3
A Long-term Extension Study of PCI-32765 (Ibrutinib)
- NCT02107989 · 700 participants
Noninvasive Pre-surgical Evaluation of Patients With Focal Epilepsy and Establishment of a Normative Imaging Database
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI